Report overview
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal Therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
This report aims to provide a comprehensive presentation of the global market for Hormone Refractory Prostate Cancer (HRPCA), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hormone Refractory Prostate Cancer (HRPCA). This report contains market size and forecasts of Hormone Refractory Prostate Cancer (HRPCA) in global, including the following market information:
Global Hormone Refractory Prostate Cancer (HRPCA) Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Hormone Refractory Prostate Cancer (HRPCA) market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Cytotoxic Agents Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Hormone Refractory Prostate Cancer (HRPCA) include Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG and Johnson & Johnson, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hormone Refractory Prostate Cancer (HRPCA) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hormone Refractory Prostate Cancer (HRPCA) Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Hormone Refractory Prostate Cancer (HRPCA) Market Segment Percentages, by Type, 2022 (%)
Cytotoxic Agents
Anti-Androgens
Vaccines
Radio-Pharmaceuticals
Global Hormone Refractory Prostate Cancer (HRPCA) Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Hormone Refractory Prostate Cancer (HRPCA) Market Segment Percentages, by Application, 2022 (%)
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others
Global Hormone Refractory Prostate Cancer (HRPCA) Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Hormone Refractory Prostate Cancer (HRPCA) Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hormone Refractory Prostate Cancer (HRPCA) revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Hormone Refractory Prostate Cancer (HRPCA) revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hormone Refractory Prostate Cancer (HRPCA), market overview.
Chapter 2: Global Hormone Refractory Prostate Cancer (HRPCA) market size in revenue.
Chapter 3: Detailed analysis of Hormone Refractory Prostate Cancer (HRPCA) company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hormone Refractory Prostate Cancer (HRPCA) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
